5.15

0.98% 0.05

After Hours: 5.09 -0.06 -1.17%

Candel Therapeutics Inc (CADL)

Overview News Price History Financials Discussions Forecast

Candel Therapeutics Inc stock is traded at $5.15, with a volume of 1.01M. It is up +0.98% in the last 24 hours and up +10.28% over the past month. Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Previous Close:

$5.10

Open:

$5.14

24h Volume:

1.01M

Relative Volume:

0.89

Market Cap:

$377.22M

Revenue:

$31,000

Net Income/Loss:

$-38.18M

P/E Ratio:

-7.3466

EPS:

-0.701

Net Cash Flow:

$-38.90M

1W Performance:

+4.04%

1M Performance:

+10.28%

6M Performance:

-13.81%

1Y Performance:

+4.04%

1-Day Range:

$5.04

$5.2025

1-Week Range:

$4.76

$5.2025

52-Week Range:

$4.3384

$7.25

Candel Therapeutics Inc Stock (CADL) Company Profile

Name

Candel Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-916-5445

Address

117 KENDRICK STREET, NEEDHAM

Employee

Twitter

Next Earnings Date

2026-03-12

Latest SEC Filings

CADL's Discussions on Twitter

Compare CADL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CADL Candel Therapeutics Inc	5.15	373.56M	31,000	-38.18M	-38.90M	-0.701
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-28-25	Initiated	Stephens	Overweight
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral
Jun-30-25	Resumed	H.C. Wainwright	Buy
Feb-20-25	Initiated	Citigroup	Buy
Feb-19-25	Initiated	Canaccord Genuity	Buy
Feb-07-25	Initiated	BofA Securities	Buy
Dec-02-22	Initiated	H.C. Wainwright	Buy
Nov-19-21	Initiated	BMO Capital Markets	Outperform
Aug-23-21	Initiated	Credit Suisse	Outperform
Aug-23-21	Initiated	Jefferies	Buy
Aug-23-21	Initiated	UBS	Buy

View All

Candel Therapeutics Inc Stock (CADL) Latest News

Apr 14, 2026

Candel Therapeutics advances viral immunotherapies in prostate lung and brain cancer programs - Traders Union

Apr 14, 2026

Apr 13, 2026

Aug Analyst Calls: Should I hold or sell Candel Therapeutics Inc now2026 Recap & AI Enhanced Execution Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN

Apr 12, 2026

Apr 08, 2026

Candel Therapeutics, Inc. prepares new immunotherapy data release at AUA2026 - Traders Union

Apr 08, 2026

Apr 07, 2026

Dow Update: Is Candel Therapeutics Inc affected by consumer sentimentMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Winners Losers: Can Candel Therapeutics Inc be the next market leaderWeekly Profit Recap & Capital Efficient Trade Techniques - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026